Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 USD | -2.78% | +1.74% | -41.86% |
03/04 | North American Morning Briefing : Powell Awaited -2- | DJ |
02/04 | Certain Warrants of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2024. | CI |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 181.9 | 300.5 | 249.1 | 71.14 | 54.57 | 33.66 | - | - |
Enterprise Value (EV) 1 | 181.9 | 300.5 | 249.1 | 71.14 | 54.57 | 33.66 | 33.66 | 33.66 |
P/E ratio | -3.52 x | -4.88 x | -3.16 x | -0.68 x | -0.36 x | -0.3 x | -0.37 x | -0.36 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | 4.97 x | 6.59 x | 3.62 x | 0.94 x | 0.65 x | 0.47 x | 0.31 x | 0.24 x |
EV / Revenue | 4.97 x | 6.59 x | 3.62 x | 0.94 x | 0.65 x | 0.47 x | 0.31 x | 0.24 x |
EV / EBITDA | -1.67 x | -3.27 x | -1.32 x | - | - | -0.2 x | -0.19 x | -0.18 x |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 4,719 | 6,320 | 6,642 | 7,241 | 18,131 | 19,235 | - | - |
Reference price 2 | 38.55 | 47.55 | 37.50 | 9.825 | 3.010 | 1.750 | 1.750 | 1.750 |
Announcement Date | 16/03/20 | 31/03/21 | 28/03/22 | 30/03/23 | 28/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 36.63 | 45.6 | 68.79 | 75.74 | 84.51 | 71.22 | 109.8 | 137.4 |
EBITDA 1 | -108.9 | -91.99 | -188.5 | - | - | -167.8 | -177.4 | -188.4 |
EBIT 1 | -110.8 | -94.27 | -188.5 | -203.6 | -142.3 | -138.8 | -124.4 | -123.5 |
Operating Margin | -302.54% | -206.74% | -274.08% | -268.76% | -168.43% | -194.87% | -113.28% | -89.91% |
Earnings before Tax (EBT) 1 | -101.7 | -102.8 | -164.4 | -213.5 | -153.6 | -147.2 | -136 | -135.6 |
Net income 1 | -39.96 | -46.53 | -64.7 | -86.58 | -68.67 | -98.06 | -95.14 | -112 |
Net margin | -109.09% | -102.03% | -94.06% | -114.3% | -81.25% | -137.69% | -86.63% | -81.55% |
EPS 2 | -10.95 | -9.750 | -11.85 | -14.55 | -8.470 | -5.800 | -4.683 | -4.920 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 16/03/20 | 31/03/21 | 28/03/22 | 30/03/23 | 28/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 21.08 | 18.28 | 23.92 | 18.89 | 16.53 | 16.4 | 12.43 | 17.39 | 34.54 | 20.59 | 14.13 | 15.31 | 23.97 | 17.81 |
EBITDA 1 | -40.38 | -62 | -47.27 | -50.93 | -50.73 | - | - | - | - | - | -52.5 | -46.2 | -43.6 | -25.5 |
EBIT 1 | -40.38 | -62 | -47.27 | -50.93 | -50.73 | -54.63 | -58.87 | -50.1 | 17.24 | -142.4 | -40.71 | -38.07 | -29.74 | -30.27 |
Operating Margin | -191.52% | -339.25% | -197.58% | -269.65% | -306.96% | -333.05% | -473.63% | -288.19% | 49.93% | -691.5% | -288.07% | -248.7% | -124.07% | -169.94% |
Earnings before Tax (EBT) 1 | -45.86 | -68.04 | -49.48 | -53.93 | -53.06 | -57 | -55.14 | -59.3 | 16.88 | -152 | -42.81 | -40.2 | -31.84 | -32.37 |
Net income 1 | -20.78 | -31.56 | -15.76 | -21.36 | -22.51 | -26.95 | -21.54 | -24.78 | 16.79 | -66.96 | -28.7 | -26.4 | -23.78 | -19.19 |
Net margin | -98.56% | -172.71% | -65.87% | -113.08% | -136.2% | -164.28% | -173.28% | -142.51% | 48.61% | -325.22% | -203.08% | -172.45% | -99.2% | -107.71% |
EPS 2 | -3.900 | -5.700 | -2.700 | -3.600 | -3.750 | -4.500 | -3.150 | -3.360 | 0.8000 | -8.380 | -1.730 | -1.577 | -1.353 | -1.153 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 15/11/21 | 28/03/22 | 12/05/22 | 11/08/22 | 14/11/22 | 30/03/23 | 15/05/23 | 14/08/23 | 07/11/23 | 28/03/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | -21.40 | -30.30 | - | - | - | - |
Capex | 2.35 | 5.96 | 4.57 | 2.72 | - | - | - | - |
Capex / Sales | 6.4% | 13.08% | 6.64% | 3.58% | - | - | - | - |
Announcement Date | 16/03/20 | 31/03/21 | 28/03/22 | 30/03/23 | 28/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.86% | 33.66M | |
-3.79% | 88.14B | |
+1.45% | 40.51B | |
-15.94% | 31.67B | |
+52.66% | 24.62B | |
-14.50% | 15.65B | |
-14.38% | 12.07B | |
-9.12% | 11.97B | |
-42.56% | 11.61B | |
+4.87% | 8.81B |
- Stock Market
- Equities
- FBIO Stock
- Financials Fortress Biotech, Inc.